Key epitope can trigger tumour cell death

By 2023-10-24T16:00:43

Chimeric,Antigen,Receptor,(car),Therapy:,Engineered,T-cell,Attacks,A,Leukemia

An epitope on CD95 receptor causes tumour cells to self-destruct and may prolong benefits of CAR T-cell therapy for solid tumours.

Already a member? Sign in

Unlock

Intelligence for the future of drug discovery

By highlighting cutting-edge research and its practical applications, Drug Target Review enables readers to make decisions that accelerate innovation, translate discoveries into therapies, and create tangible benefits for patients worldwide.

Become a member to continue reading

By becoming a member you join a connected and collaborative community driving the industry forward. Member benefits include:

  • Unlimited access to industry intelligence that can make a difference to your business
  • A weekly newsletter keeping the most vital information at the front of your thinking
  • Exclusive invitations to powerful webinars and events featuring high profile experts
  • Access to deep-dive reports and analysis that reveal exciting new opportunities for business growth and transformation

Become a member